Daniel is joining the Duke Capital Partners team as an Assistant Director. He previously worked with the team for three years as an Associate and then Lead Ph.D. Associate. Daniel has been a postdoc with the Duke SOM Pharmacology and Cancer Biology department since 2019. Before that, he was with a neurodegenerative therapeutics start-up for a year. Daniel earned a Ph.D. in Toxicology from Iowa State University and an undergraduate degree from Penn State.